• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

In-hospital gastrointestinal bleeding in patients with acute myocardial infarction: incidence, outcomes and risk factors analysis from China Acute Myocardial Infarction Registry
Conclusions GIB is associated with both in-hospital and follow-up MACCEs. Gastrointestinal prophylactic treatment should be administered to patients with AMI who receive primary PCI, thrombolytic therapy or GPIIb/IIIa receptor inhibitor. Trial registration number NCT01874691.
Source: BMJ Open - September 7, 2021 Category: General Medicine Authors: Shi, W., Fan, X., Yang, J., Ni, L., Su, S., Yu, M., Yang, H., Yu, M., Yang, Y., On behalf of China Acute Myocardial Infarction(CAMI) Registry Study Group Tags: Open access, Cardiovascular medicine Source Type: research

Current Perspectives in Facilitated Angioplasty
Conclusions: With the current increased burden of acute coronary syndromes and the lack of immediate primary PCI facilities for all patients with STEMI, facilitated angioplasty seems a feasible therapeutic option. Another benefit of facilitated angioplasty may be represented by a major contribution of thrombolytic therapy in re-establishing microvascular myocardial blood flow.
Source: American Journal of Therapeutics - March 1, 2019 Category: Drugs & Pharmacology Tags: Systematic Reviews Source Type: research

Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Abstract Poly(ADP-ribosyl)ation is an immediate cellular repair response to DNA damage and is catalyzed primarily by poly(ADP-ribose)polymerase-1 (PARP1), which is the most abundant of the 18 different PARP isoforms and accounts for more than 90% of the catalytic activity of PARP in the cell nucleus. Upon detection of a DNA strand break, PARP1 binds to the DNA, cleaves nicotinamide adenine dinucleotide between nicotinamide and ribose and then modifies the DNA nuclear acceptor proteins by formation of a bond between the protein and the ADP-ribose residue. This generates ribosyl-ribosyl linkages that act as a signal...
Source: Cardiovascular Toxicology - July 2, 2018 Category: Cardiology Authors: Henning RJ, Bourgeois M, Harbison RD Tags: Cardiovasc Toxicol Source Type: research

Thrombolytic Therapy In The Current Era: Myocardial Infarction And Beyond.
This article summarizes the history, evidence base and current use of thrombolytics in cardiovascular disease. . PMID: 29283052 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - December 27, 2017 Category: Drugs & Pharmacology Authors: Proctor P, Leesar MA, Chatterjee A Tags: Curr Pharm Des Source Type: research

Pathophysiologic role of ischemia reperfusion injury: a review
Publication date: Available online 19 June 2017 Source:Journal of Indian College of Cardiology Author(s): Vishal Kumar Vishwakarma, Prabhat Kumar Upadhyay, Jeetendra Kumar Gupta, Harlokesh Narayan Yadav Ischemic heart disease (IHD) is the major cause of morbidity and mortality all over the world. World health organization (WHO) in 2002 assumed that IHD may be the major leading cause of death by 2020. An estimated 17 million people died from cardiovascular diseases (CVS) globally. Of these deaths, 7 million people died by ischemia heart disease and 6.2 million by stroke. Ischemia is defined as an insufficient supply of the...
Source: Journal of Indian College of Cardiology - June 19, 2017 Category: Cardiology Source Type: research

Comparison of antithrombotic agents during urgent percutaneous coronary intervention following thrombolytic therapy: A retrospective cohort study
ConclusionIn STEMI patients undergoing PCI within 24 hr after thrombolytic therapy, bivalirudin was associated with a strong trend toward reduced bleeding complications as compared to heparin alone or heparin plus GPI.The optimal antithrombotic regiment for urgent PCI following thrombolytic therapy is currently unknown. Our study demonstrated that use of bivalirudin during PCI following thrombolytic therapy is associated with a trend toward reduced bleeding complications compared to heparin alone or heparin plus GPI. Large randomized trials of adjunctive anticoagulation during PCI in this complex post‐thrombolytic popula...
Source: Catheterization and Cardiovascular Interventions - April 18, 2017 Category: Cardiovascular & Thoracic Surgery Authors: Jaya R. Mallidi, Peter Robinson, Paul F. Visintainer, Amir S. Lotfi, Scott Mulvey, Gregory R. Giugliano Tags: Coronary Artery Disease Source Type: research

Thrombolytic therapy-associated acute myocardial infarction in patients with acute ischemic stroke: A treatment dilemma
Acute myocardial infarction (AMI) is uncommon in the acute phase of acute ischemic stroke (AIS) and occurs in approximately 1% of the population. Here, we report a paradoxical case of AMI during tissue plasminogen activator (t-PA) infusion for AIS. We review and analyze the previously reported cases. We found that only patients with AMI which occurred after thrombolytic therapy for AIS who received an adequate combination of anticoagulation plus percutaneous coronary intervention survived their events.
Source: The American Journal of Emergency Medicine - November 21, 2016 Category: Emergency Medicine Authors: Chih-Jen Yang, Po-Chuan Chen, Chin-Sheng Lin, Chia-Lin Tsai, Shih-Hung Tsai Source Type: research

Clinical characteristics, management and 1-year outcomes of patients with acute coronary syndrome in Iran: the Iranian Project for Assessment of Coronary Events 2 (IPACE2)
Conclusions Our study showed that the composition of Iranian patients with ACS regarding the type of ACS is similar to that in developed European countries and is unlike that in developing countries of the Middle East and Africa. We found that our patients with ACS are treated with high levels of adherence to guideline-recommended in-hospital medications.
Source: BMJ Open - December 15, 2015 Category: Journals (General) Authors: Kassaian, S. E., Masoudkabir, F., Sezavar, H., Mohammadi, M., Pourmoghaddas, A., Kojouri, J., Ghaffari, S., Sanaati, H., Alaeddini, F., Pourmirza, B., Mir, E., on-behalf of the IPACE2 registry investigators Tags: Open access, Cardiovascular medicine, Evidence based practice, Medical management Research Source Type: research

Simultaneous thrombosis of 2 vascular territories: is thrombolytic therapy a better option?
We have read with great interest the article by Akyuz and colleagues in the American Journal of Emergency Medicine and congratulate them for their observation. Their case exemplifies the concurrent occurrence of ST-segment elevation myocardial infarction (STEMI) and posterior circulation stroke that was eventually managed with thrombolytic therapy. Simultaneous thrombosis of 2 distant vascular territories is a rare and complicated clinical scenario. In these instances, there is usually an underlying cause linking both thrombotic events rather than being a mere coincidence. We have previously described the myocardial infarc...
Source: The American Journal of Emergency Medicine - July 1, 2013 Category: Emergency Medicine Authors: Hesham R. Omar, Devanand Mangar, Enrico M. Camporesi Tags: Correspondence Source Type: research

Relationship Between ST-Segment Recovery and Clinical Outcomes After Primary Percutaneous Coronary Intervention: The HORIZONS-AMI ECG Substudy Report Myocardial Infarction
Conclusions— In this large international study, absent STR 60 minutes after primary PCI was present in 1 in 5 patients with ST-segment–elevation myocardial infarction and was a significant independent predictor of major adverse cardiovascular events and target vessel revascularization at 3 years. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00433966
Source: Circulation: Cardiovascular Interventions - June 18, 2013 Category: Cardiology Authors: Farkouh, M. E., Reiffel, J., Dressler, O., Nikolsky, E., Parise, H., Cristea, E., Baran, D. A., Dizon, J., Merab, J. P., Lansky, A. J., Mehran, R., Stone, G. W. Tags: Electrocardiology, Catheter-based coronary interventions: stents, Acute myocardial infarction Source Type: research

Rescue thrombolysis in the treatment of cardiac shock and acute stroke
The patients with ST-elevation myocardial infarction are primarily managed with percutaneous coronary intervention (PCI) or thrombolysis. It is well accepted that rescue PCI should be implemented in case of unsuccessful thrombolysis. However, the reverse, rescue thrombolysis, that is, administering of thrombolytic therapy in a patient in whom primary PCI fails, is not well defined. There are no available data about rescue thrombolysis so far. We represent a 43-year-old male patient with Buerger disease (thromboangiitis obliterans) who was admitted to our emergency department for cardiac shock related to inferior and right ...
Source: The American Journal of Emergency Medicine - April 19, 2013 Category: Emergency Medicine Authors: Sukru Akyuz, Mustafa Azmi Sungur, Cevdet Donmez, Aylin Sungur, Nese Cam Tags: Case Reports Source Type: research

Primary Percutaneous Coronary Intervention: The Deception of Delay⁎
Primary percutaneous coronary intervention (PCI) has become the predominant reperfusion strategy for ST-segment elevation myocardial infarction (STEMI) throughout western healthcare systems. Recent estimates in the United States suggest that primary PCI is used in 85% of all STEMI cases that undergo reperfusion, with thrombolytic agents used in only 9% and the combination of thrombolytic agents with PCI in 6% (). This dramatic switch from thrombolytic therapy to primary PCI was the result of several studies conducted in the early 1990s that demonstrated the superiority of primary PCI at reducing stroke and reinfarction as ...
Source: Journal of the American College of Cardiology - April 17, 2013 Category: Cardiology Authors: Cindy L. Grines, Theodore Schreiber Tags: Acute Coronary Syndromes: Editorial Comment Source Type: research

Primary Percutaneous Coronary Intervention The Deception of Delay ⁎ ⁎
Primary percutaneous coronary intervention (PCI) has become the predominant reperfusion strategy for ST-segment elevation myocardial infarction (STEMI) throughout western healthcare systems. Recent estimates in the United States suggest that primary PCI is used in 85% of all STEMI cases that undergo reperfusion, with thrombolytic agents used in only 9% and the combination of thrombolytic agents with PCI in 6% (1). This dramatic switch from thrombolytic therapy to primary PCI was the result of several studies conducted in the early 1990s that demonstrated the superiority of primary PCI at reducing stroke and reinfarction as...
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - April 15, 2013 Category: Cardiology Source Type: research

The outcome of intra-aortic balloon pump support in acute myocardial infarction complicated by cardiogenic shock according to the type of revascularization: A comprehensive meta-analysis
Aims: Despite the recommendations of the current guidelines, scientific evidence continue to challenge the effectiveness of intra-aortic balloon pump (IABP) in acute myocardial infarction (AMI) complicated by cardiogenic shock. Moreover, 2 recent meta-analyses showed contrasting results. The aim of this study is to test the effect of IABP according to the type of therapeutic treatment of AMI: percutaneous coronary intervention (PCI), thrombolytic therapy (TT), or medical therapy without reperfusion. Articles published from January 1, 1986, to December 31, 2012, were collected and analyzed by meta-analysis.Methods and resul...
Source: American Heart Journal - March 27, 2013 Category: Cardiology Authors: Francesco Romeo, Maria Cristina Acconcia, Domenico Sergi, Alessia Romeo, Saverio Muscoli, Serafina Valente, Gian Franco Gensini, Flavia Chiarotti, Quintilio Caretta Tags: Curriculum in Cardiology Source Type: research

Pages: 1  2